anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The method can be applied in inpatient and outpatient medical practice. Using the clinoptilolite mineral there are facilities for making detailed, quick, quality and reliable diagnostics of different diseases. The clinoptilolite is heat treated and sterilized at 150-250 degrees C and has ( 0.1 mm particle sizes. To a patient subject to diagnostics intended to clean his organism from waste protein products, doses of 2.5 to 5 g 1-4 times a day are administer for 2 to 5 days. During this period any changes of the concentration of the urine clearing substances is monitored. The clinoptilolite administration is discontinued when the concentration drops to a level allowing the observation of spheroliths, anisotropic and isotropic structures of the , contained in the urine, amidinoureic phosphates, potassium-sodium triphosphates and potassium chloride, produced in the polymorphic conversion of the potassium-sodium enzymic complexes of the adenosine triphosphate hydrate contained in the organism. In the diagnostics, dry and/or oversaturated solution is tested by means of a polarizing microscope and light-sensitive gypsum plate with 540 (m difference in the course of the light waves. Identification is made of the anisotropic protein-containing crystalline mineral structures of the amidinoureic phosphates, potassium-sodium triphosphates and potassium-chloride structures of the isotropic crystals the morphologic characteristics of which corresponds to a healthy or a morbid organism for different diseases. After the purification in the dry residue of the patient's urine by means of X-ray structural analysis of the potassium-sodium amidinoureic phosphate hydrate complexes, and/or powder phase X-ray analysis of these complexes. The results produced are compared with the first reference for adenosine triphosphate hydrate contained in the living organism, and with a second reference for the potassium chloride contained in the organism. Judgement for the health condition of the tested patient is made from any deviation of these data from the reference ones. It is possible that the freshly taken patient's urine can be pretreated with neutralized NaHCO3 solution of ascorbic acid (vitamin C) with pH from 5 to 7 to vitamin C concentration from 30 to 100 mg per 100 ml urine, after which  from 15 to 60 minutes is awaited and preparation is started of the dry residue or of the oversaturated solution for further investigations. 16 claims, 58 figures
Dihydroergotamine Mesylate Injection, USP should not be used by patients with documented ischemic or vasospastic coronary artery disease. (See CONTRAINDICATIONS.) It is strongly recommended that Dihydroergotamine Mesylate Injection, USP not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, females who are surgically or physiologically postmenopausal, or males who are over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery vasospasm is modest, at best. If, during the cardiovascular evaluation, the patient's medical history or electrocardiographic investigations reveal findings indicative of or consistent with coronary artery vasospasm or myocardial ischemia, Dihydroergotamine Mesylate Injection, USP should not be administered. (See CONTRAINDICATIONS)

For patients with risk factors predictive of CAD who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of Dihydroergotamine Mesylate Injection, USP take place in the setting of a physician's office or similar medically staffed and equipped facility unless the patient has previously received dihydroergotamine mesylate. Because cardiac ischemia can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an electrocardiogram (ECG) during the interval immediately following Dihydroergotamine Mesylate Injection, USP, in those patients with risk factors.

It is recommended that patients who are intermittent long-term users of Dihydroergotamine Mesylate Injection, USP and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use Dihydroergotamine Mesylate Injection, USP.

The systematic approach described above is currently recommended as a method to identify patients in whom Dihydroergotamine Mesylate Injection, USP may be used to treat migraine headaches with an acceptable margin of cardiovascular safety.
An environmental, health and safety (EH&S) compliance system provides for real-time exchange of EH&S data from various remote and disparate data sources. These sources are typically located within a client's firewall and accessed using a data uploader component. The data are then sent securely to a data importer, which can reside either behind the client's firewall or hosted externally. The importer is the main component that accepts the data from the data uploader. The data importer can also accept data securely from the client's internal system when prohibited by the client's security policy to allow inside the firewall polling. The uploader resides usually behind the client's firewall, typically on a central server and comprises an intuitive user interface and underlying secure architecture to facilitate data transfer. It preferably has a user interface to enable client-side control. The uploader component utilizes the secure data access technologies such as from Microsoft Corporation and other third party providers to connect to and integrate with disparate data sources while utilizing an extensible markup language (XML) Web Service technology to securely transfer data to the importer component. Usually the data are acquired by receiving exported data from third-party system or by interfacing with those systems using application programming interfaces or other access techniques.
BACKGROUND: Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen in a pressurized chamber, increasing tissue oxygen levels and regulating inflammatory pathways. Mounting evidence suggests that HBOT may be effective for inflammatory bowel disease. Our systematic review and meta-analysis aimed to quantify the efficacy and safety of HBOT in fistulizing Crohn's disease (CD).
METHODS: A systematic review was conducted using the EMBASE, Web of Science, Pubmed, and Cochrane Library databases according to the "Preferred Reporting Items for Systematic Reviews and Meta-analyses" criteria. Study bias was assessed using the Cochrane Handbook guidelines.
RESULTS: Sixteen studies with 164 patients were included in the analysis. For all fistula subtypes, the pooled overall clinical response was 87% (95% CI: 0.70-0.95, I2 = 0) and the pooled clinical remission was 59% (95% CI: 0.35-0.80, I2 = 0). The overall clinical response was 89%, 84%, and 29% for perianal, enterocutaneous, and rectovaginal fistulas, respectively. On meta-regression, hours in the chamber and the number of HBOT sessions were not found to correlate with clinical response. The pooled number of adverse events was low at 51.7 per 10,000 HBOT sessions for all fistula types (95% CI: 16.8-159.3, I2 = 0). The risk of bias was observed across all studies.
CONCLUSION: HBOT is a safe and potentially effective treatment option for fistulizing CD. Randomized control trials are needed to substantiate the benefit of HBOT in fistulizing CD.
BACKGROUND: We determined the left ventricular end-systolic diameter (LVDs) cut-off value for risk of major adverse cardiac and cerebrovascular events (MACCE) in Japanese asymptomatic or mildly symptomatic patients undergoing aortic valve replacement (AVR) for aortic valve regurgitation (AR), and investigated the effect of left ventricular dilation on long-term postoperative outcomes.Methods and Results: The 168 patients who underwent surgical AVR for AR at Shiga University of Medical Science between January 2002 and December 2022 were included in this study. Receiver operating characteristic curve analysis showed that the cut-off value of preoperative LVDs for the incidence of MACCE was 42.8 mm (area under the curve 0.616). Postoperative outcomes were compared between patients with preoperative LVDs >42.8 mm (n=77) and those with preoperative LVDs ≤42.8 mm (n=91) using propensity score matching. The 10-year estimated rates of freedom from MACCE in those with LVDs >42.8 and ≤42.8 mm were 59.9% and 85.7%, respectively; the curves differed significantly (P=0.004). In multivariable Cox proportional hazard regression analyses, preoperative LVDs >42.8 mm was an independent predictor of MACCE (hazard ratio 2.485; 95% confidence interval 1.239-4.984; P=0.010).
CONCLUSIONS: Preoperative LVDs >42.8 mm is associated with an increased risk of MACCE in Japanese patients undergoing AVR for AR.
Intracerebral hemorrhage(ICH) accounts for approximately a quarter of all stroke subtypes with high mortality and the survi- vors always have varying degrees of residual disability. However, few medical and surgical treatments are clearly beneficial comparing with ischemic stroke. Hematoma expansion, which is a determinant of poor outcomes, occurs in about 30% of ICH patients especially at the early stage. Attenuating hema- toma expansion is a compelling target for ICH treatment, while the outcomes have not been accordingly improved after curbing the growth of hematoma in several clinical trials. It will be more helpful if a predictor can identify the risk of hematoma expansion and poor outcome rapidly and accurately. Thus the antiexpansion treatment to the patients with positive of such predictor is likely to provide clinical benefits.
The study will include 100 patients between the ages of 18 and 65, diagnosed with heel spurs, who meet the inclusion and exclusion criteria in the Algology and PMR (Physical medicine and rehabilitation) departments of Kanuni Sultan Süleyman Training and Research Hospital, between May 2024 and August 2024 (Standard effect As a result of the power analysis, it was deemed appropriate to include at least 22 cases in each group with a power of 80% and a margin of error of 0.84 . According to this result, a total of 100 patients will be included in the study, taking into account the losses ). Randomization will be done using a randomization program to divide patients into two groups and assign a number to each patient.

The power analysis, it was deemed appropriate to include at least 22 cases in each group , with a standard effect size of 0.84, with 80% power and 5% margin of error . According to this result, a total of 100 patients will be included in the study, taking into account losses .) The posterior tibial nerve will be performed by the same algologist . Patients will be monitored standardly (Noninvasive blood pressure, pulse oximeter, electrocardiogram) and will be performed in the supine position at TCPRF . For TCPRF, a 45\*98 mm diameter transcutaneous electrode (FIAB SPA, Italy ) will be used. Electrode medial at ankle level It will be placed posterior to the malleolus , in the posterior tibial nerve trace accompanying the artery after palpation of the posterior tibial artery . TCPRF will be applied for 8 minutes at 80 volts, 2 Hz, 20 ms . The process will be repeated 3 times with a one-week interval.

To the control group with the radial ESWT device. Vibrolith An Orto® brand electro- pneumatic , extracorporeal shock wave therapy device will be used. It will be applied by the same physiotherapist with at least 10 years of experience in the field. Sick It will be in the prone position and ESWT will be applied to the spur area as a radial type shock wave . The process will be repeated 3 times with a one-week interval. Sessions will be applied with 10 Hz frequency, 2000 beats, 2.5 bar intensity.

Patient evaluation and results will be made by another algologist (FAE) who is unaware of the type of treatment. Demographic data of the patients, body mass index (BMI), symptom duration, additional diseases, medical treatments, the side where the procedure was performed, rest and activity Numeric Rating Scale -11 ( NRS) and Foot function index ( Foot ) function index , FFI) will be recorded before the procedure and in the 1st and 3rd months after the procedure. NRS-11 is an 11-point numerical scale in which patients can evaluate their pain between 0 (no pain) and 10 (the most severe pain they have ever felt in their life) . FFI is a validated scale consisting of 23 questions in total, including 3 subgroups : pain, disability and activity limitation .
1330360 Steroid talomethylosides DR KARL THOMAE GmbH 2 Nov 1971 [2 Nov 1970 25 Sept 1971] 50939/71 Heading C2U The invention comprises compounds of formula wherein R 1  and R 2  are each H or C 2-4  alkanoyl, or together represent a -C(A)(B)- group in which A is H or Me and B is Me or Ph, or A, B and the intervening carbon atom together form a 6- or 7-membered cycloaliphatic ring; R 3  is H, C 2-4  alkanoyl or the acyl radical of a heterocyclic carboxylic acid; R 4  is CH 3 , CHO or CH 2 OH; R 5  is a 20(22)-cardenolide or 20, 22-bufadienolide lactone ring; R 6  is H and R 7  is H or OH or R 6  and R 7  together represent an additional 4,5- bond; with the provisos that (i) when R 5  is a cardenolide lactone ring and R 4  is CHO or CH 2 OH, then at least one of R 1 , R 2  and R 3  is other than H; and (ii) when R 5  is a bufadienolide lactone ring, then R 7  is other than H. Compounds I are prepared (a) by reduction of the 4<SP>1</SP>-oxo group in compounds of Formula II or (b) by reacting a compound of Formula III with a compound of Formula IV wherein R 4 <SP>1</SP> is CH 3  or CHO, Hal is Cl or Br and Ac is acyl. Method (a) (which may also be used for the preparation of compounds I which violate proviso (i) above) may be effected with a complex metal hydride and may result in partial or complete reduction of any 19-oxo group to hydroxy. Method (b) may be effected in the presence of Ag 2 O, Ag 2 CO 3 , Hg(CN) 2 , pyridine or 2,6-lutidine, and, when the groups Ac are other than as defined for R 1 , R 2  and R 3 , they must be removed. The products of methods (a) and (b) are convertible into other compounds of Formula I by esterification, acetalization, ketalization, hydrolysis of ester, acetal and ketal groups, and reduction of 19-oxo to hydroxy. Compounds II wherein R 1  and R 2  together represent a -C(A)(B)- group as defined above, are prepared by oxidation of the corresponding acetalized or ketalized α-L-rhamnosides. Compounds I are said to be cardioactive, and may be made up with carriers into pharmaceutical compositions for oral, rectal or parenteral administration.
Oxytocin (OT) regulates food intake and body weight, particularly in obese individuals. Decreases in the effects of OT have recently been implicated in metabolic disturbances, and the administration of estradiol (E2) increased serum OT levels. Although weight gain is frequently observed in perimenopausal women, endogenous OT levels remain unclear. Therefore, we herein compared endogenous levels of hypothalamic and serum OT between young and middle-aged perimenopausal female rats and examined the relationship between serum estrogen and leptin levels. Body weight and visceral and subcutaneous fat weights were higher in middle-aged rats. Although no significant differences were observed in serum OT and E2 levels, serum leptin levels and hypothalamic mRNA levels of OT and the OT receptor (OTR) were significantly higher in middle-aged rats than in young rats. Serum OT levels did not correlate with hypothalamic OT mRNA levels or serum E2 levels. E2 maintains serum OT levels in perimenopausal rats, and other factors may elevate hypothalamic OT/OTR mRNA levels. Increases in body and fat weights in perimenopausal rats may be attributed to factors other than OT. Therefore, the administration of OT alone may not be sufficient to prevent metabolic disorders induced by the perimenopausal status. J. Med. Invest. 71 : 246-250, August, 2024.
It is recommended that MYCOBUTIN Capsules be administered at a dose of 300 mg once daily. For those patients with propensity to nausea, vomiting, or other gastrointestinal upset, administration of MYCOBUTIN at doses of 150 mg twice daily taken with food may be useful.

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), consider reducing the dose of MYCOBUTIN by 50%, if toxicity is suspected. No dosage adjustment is required for patients with mild to moderate renal impairment. Reduction of the dose of MYCOBUTIN may also be needed for patients receiving concomitant treatment with certain other drugs (see PRECAUTIONS-Drug Interactions).

Mild hepatic impairment does not require a dose modification. The pharmacokinetics of rifabutin in patients with moderate and severe hepatic impairment is not known.
Individually adjusted biphasic insulin aspart 30 injected subcutaneously twice daily with meals (breakfast and dinner) and administered in combination with current OAD treatment. In the second and third years, a second insulin formulation was added if subjects failed to achieve or to maintain good glycaemic control, defined as two consecutive HbA1c measurements exceeding 6.5% or a single measurement exceeding 7.5%. Subjects randomised to biphasic insulin aspart twice daily were asked to add insulin aspart at lunchtime (midday) i.e. an augmented pre-mixed insulin analogue regimen.
The present invention has found that seaweed and banana peels, which typically would not exhibit any observable inhibitory effect on bacteria and fungi, exhibit inhibitory effects on bacteria and fungi when combined with an apple surfactant. Additionally, it was found that banana peels readily break down proteins and fats through a ninhydrin reaction and a reaction with a Sudan reagent, whereas the apple surfactant breaks down the same to a similar degree as a regular synthetic surfactant. The result of this study was applied to a dandruff patient over three months to find that the dandruff on the scalp gradually disappeared and improved until the scalp finally reached a level similar to the normal scalp. Additionally, it was confirmed that when using extracts of seaweed and banana peels, proteins are readily broken down, and antioxidant effect and trouble alleviating effect provide a sufficient effect for alleviating dandruff. With the antioxidant experiment and acidity measurement that support the above result, it was concluded that shampoo compositions need to be mixed scientifically based on chemical analysis. Additionally, since products using the seaweed extract, the apple surfactant, and banana peels are relatively inexpensive to manufacture, such products may be useful for those who are reluctant to pursue the treatment of scalp-related disorders due to the financial burden.
Pseudo stimulation mimicked the tactile and acoustic sensations of rTMS by flipping the head, at 90 degrees to the scalp, with other intervention parameters remaining consistent with the study group. For medication: If the depressive episode is only monophasic, give sertraline hydrochloride tablets 1-2 tablets/day for treatment； if the patient has bipolar disorder-depressive episode, give the emotion stabilizer lithium carbonate tablets 0.5-1.0 g/day (adjust the dose according to the blood concentration) for treatment.
OBJECTIVES: This study assessed the uptake of hormone replacement therapy (HRT) in cervical cancer patients with iatrogenic menopause. Survival in relation to HRT use was assessed via a retrospective chart study, and the severity of menopausal symptoms, motivations and barriers to starting HRT were examined via questionnaires.
STUDY DESIGN: In total, 293 women under the age of 51 and treated with radiotherapy for cervical cancer between 2010 and 2020 were identified. Medical records were searched for information on HRT use. If still living, women were sent digital questionnaires addressing menopausal symptoms, quality of life (QoL) and potential barriers and motivations concerning HRT use. Univariable data were analysed using Mann-Whitney U, chi-square, and Fisher's exact test, while logistical regression was used to analyse relationships between certain variables and use of HRT and survival.
RESULTS: Overall HRT uptake was 78.1 %, which was related to age and Charlson Comorbidity Index, but independent of the duration of radiotherapy or FIGO stage. Overall survival was higher for HRT users (χ2(1) = 4.3, p = 0.038). Questionnaires were sent to 193 patients and 100 completed it (response rate 51.8 %). Main reasons for HRT use were relief of hot flushes and improvement in QoL. For women below age 51, QoL was indeed higher for current HRT users than for non-HRT users (EQ-index 0.8 vs. 0.7, p = 0.008).
CONCLUSIONS: HRT prescription rate was inversely correlated with age. Survival was not negatively affected by HRT use. It is important to stress the benefits of HRT and address women's fears regarding its use.
PURPOSE: A method for synthesizing 6-O-cinnamyl-L-ascoarbic acid using enzyme is provided to obtain a large amount of 6-O-cinnamyl-L-ascoarbic acid derivatives with high stability to heat and light. CONSTITUTION: A method for synthesizing 6-O-cinnamyl-L-ascoarbic acid using enzyme comprises: a step of dissolving L-ascorbic acid and cinnamic acid in an organic solvent(step 1); a step of adding enzyme and stirring(step 2); and a step of filtering and drying the reactant(step 3). The organic solvent is tert-butanol, acetone, dioxane, or tert-pentanol. The cinnamic acid contains cinnamic acid ester including vinyl cinnamic acid, vinyl cinnamic acid, ethyl cinnamic acid, or isobutyl cinnamic acid. The enzyme is Candida antartica lipase. A cosmetic composition contains 6-O-cinnamyl-L-ascoarbic acid derivatives.
PROBLEM TO BE SOLVED: To suitably use the alloy for repairing dental crowns, decorative parts, contacts of electric apparatus or the like by allowing it to have a specified compsn. contg. Au, Pd, In, Cu, Zn, Pt, and the balance essential Ag and allowing it to optionally contain Al or the like. SOLUTION: This alloy has a compsn. contg. 2 to 30% Au, 15 to 35% Pd, 5 to 22% In, 0.5 to 12% Cu, 0.1 to 10% Zn, 0.1 to 10% Pt, and the balance Ag, and, moreover, in the case Al, Si, Re, Ga, Sn, In, Os, Ph and Ru are incorporated therein, each content is controlled to 0.01 to 3%. By controlling the ranges of Au and Pd to the ones similar to those in a copper-contg. low karat gold alloy placed on the market, various characteristics which can get through JIS standards are imparted thereto. In reduces the m.p. of the alloy, covers the lack of the improvement of its discoloration resistance and corrosion resistance caused by Au and Pd and moreover improves its strength. Zn effectively works as a deoxidizer for the alloy and furthermore improves its strength and corrosion resistance.